# Medicare's New Path to GLP-1 Coverage for Weight Loss
Medicare launched a five-year pilot program that covers GLP-1 receptor agonist drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) specifically for weight loss. This marks the first time the federal insurance program covers these medications for obesity alone, without requiring a diabetes diagnosis.
The pilot targets Medicare beneficiaries with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension or sleep apnea. Participants must also receive intensive behavioral therapy alongside medication use.
Eligibility extends to about 3.4 million Medicare beneficiaries. Those enrolled pay standard Medicare cost-sharing, typically ranging from 20 to 35 percent of the drug's cost after meeting their deductible, depending on whether they use original Medicare or a Medicare Advantage plan. Monthly out-of-pocket costs can still reach hundreds of dollars, making affordability a barrier for many seniors on fixed incomes.
The program requires participating doctors to monitor patients regularly and document weight loss progress. If patients don't lose at least five percent of their baseline weight within six months, or maintain that loss threshold, providers must discontinue treatment.
This pilot addresses a significant gap in coverage. Obesity affects roughly 42 percent of American adults, and even higher percentages of seniors face weight-related health challenges. GLP-1 drugs have demonstrated effectiveness in clinical trials, with users typically losing 15 to 22 percent of body weight when combined with lifestyle changes.
However, the program faces practical constraints. Supply remains limited, and not all Medicare Advantage plans participate equally. Seniors in rural areas may struggle to find participating providers. Additionally, the behavioral therapy requirement,